BCAX: Bicara Therapeutics Inc Narx/daromad koeffitsiyenti

Bicara Therapeutics Inc (BCAX) kompaniyasining korporativ logotipi

Bicara Therapeutics Inc. (BCAX) bosh va bo'yin o'smalarini davolash uchun ficerafusp alfa preparatini ishlab chiqmoqda va FDA tasdig'ini olishni maqsad qilgan. Kompaniyaga tegishli strategiya yakuniy sinovlar tugagandan so'ng bispesifik antitelalarni tijoratlashtirishga asoslangan. Bozor kapitalizatsiyasining daromadga nisbati baholash tendentsiyasini aks ettiradi va joriy ko'rsatkich ni tashkil etadi. Dori vositalarini joriy etishdagi moslashuvchanlik ishlab chiqarish va taqsimotning tashqi boshqaruvi orqali ta'minlanadi.

BCAX Bicara Therapeutics Inc.: P/S multiplikatori 04.07.2022 - 14.11.2026 oraligʻida

Bicara Corp (BCAX) kompaniyasining tahliliy kesimlari

- joriy narx va aksiyalarning prognoz qilingan qiymati:
Narx grafigi Bicara Therapeutics|BCAX - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi haqida ma'lumot:
Bozor kapitallashuvi Bicara Corp|BCAX - Korxona qiymati
- kompaniyaning balans qiymati tafsilotlari:
Bitta aksiya uchun buxgalteriya qiymati Bicara Therapeutics|BCAX - Balans kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati bicara.com|BCAX - Kompaniyaning jami aktivlari
- qarz majburiyatlari va likvidlik statistikasi:
Barcha qarzlarning o‘z mablag‘lariga nisbati Bicara Therapeutics Inc.|BCAX - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati Bicara Therapeutics|BCAX - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Bicara Therapeutics Inc.|BCAX - Kompaniyaning uzoq muddatli majburiyatlari|Qisqa muddatli majburiyatlar miqdori Bicara Therapeutics|Oraliq qoplash koeffitsiyenti bicara.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
BCAX - Sof foyda|Kutilayotgan sof foyda Bicara Therapeutics Inc.|BCAX - Narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori Bicara Bio|BCAX - PEG multiplikatori|EV/EBITDA multiplikatori Bicara Therapeutics|BCAX - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|So'nggi 12 oy davomida bitta aksiya uchun foyda Bicara Therapeutics|BCAX - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida yillik hisobda bir aksiya uchun foyda o'sishi bicara.com|BCAX - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Bicara Therapeutics Inc.
- emitentning tushumi va sotuvlari tafsilotlari:
BCAX - Kompaniya savdosi|Kompaniyaning prognoz qilingan daromad hajmi Bicara Therapeutics|BCAX - P/S multiplikatori|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Bicara Corp
Kompaniyaning jamlanma tahliliyoti:Bicara Bio, BCAX
Bicara Bio tayyor mahsulotlari

Emitentni xolis baholash uchun bozor kapitalizatsiyasining yillik daromadga nisbatini tushunish juda muhimdir, chunki bu ko'rsatkich biznesning savdo hajmini oshirish qobiliyatiga nisbatan to'langan premium miqdorini belgilaydi. Narx/savdo nisbatini tahlil qilish orqali investor qiymatning normadan matematik og'ishlarini aniqlaydi, bu esa ayniqsa Bicara Therapeutics Inc. (BCAX) uchun dolzarbdir, chunki onkologik dori vositalarini ishlab chiqishdan olinadigan epizodik daromadlar joriy baholashni klinik sinovlar kutilmalariga bog'liq qiladi.

Bicara Therapeutics Inc. kimlar bilan raqobatlashadi

ONC - Sotuvga nisbatan narx|P/S multiplikatori HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Sotuvga nisbatan narx|ascentage.com - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati CGON (cgoncology.com)|URGN: P/S multiplikatori|PSNL - Narx/daromad koeffitsiyenti|ERAS (Erasca Oncology) - P/S multiplikatori|P/S multiplikatori Delcath Systems, Inc.|Narxning daromadga nisbati ymabs.com (YMAB)|Narxning daromadga nisbati AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Kapitalizatsiyaning daromadga nisbati|Accuray Inc. (ARAY) - Sotuvga nisbatan narx|SELLAS Life Sciences Group, Inc. - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Narxning daromadga nisbati|HURA - Narx/daromad koeffitsiyenti|TARA (Protara Therapeutics, Inc.) - P/S multiplikatori|P/S multiplikatori Fate Therapeutics Inc|P/S multiplikatori WHWK|P/S multiplikatori TScan Therapeutics Inc (TCRX)|Narxning daromadga nisbati championsoncology.com CSBR|XBIT - Kapitalizatsiyaning daromadga nisbati|CVM - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati OSTX (OS Therapies)|RADX: P/S multiplikatori|Artiva Biotherapeutics Inc. - Bozor kapitallashuvining daromadga nisbati|ANL (Adlai Nortye) - P/S multiplikatori|P/S multiplikatori verupharma.com|Kapitalizatsiyaning daromadga nisbati TPST (tempesttx.com)|Kapitalizatsiyaning daromadga nisbati Xilio Therapeutics Inc XLO|P/S multiplikatori RENB (Enochian BioSciences)|Mural Bio - Narxning daromadga nisbati|KAPA - Narxning daromadga nisbati|OnKure Therapeutics (OKUR) - Kapitalizatsiyaning daromadga nisbati|GDTC: P/S multiplikatori|Sotuvga nisbatan narx Curis Corp (CRIS)|APLM (apollomicsinc.com) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Tharimmune Corp (THAR)|P/S multiplikatori ADVB|GNPX - Sotuvga nisbatan narx|Narxning daromadga nisbati calidibio.com CLDI|SBFM - Kapitalizatsiyaning daromadga nisbati|XBIO - Narxning daromadga nisbati|SLRX: Narxning daromadga nisbati|Purple Biotech (PPBT) - Narxning daromadga nisbati|AON - Bozor kapitallashuvining daromadga nisbati|Kapitalizatsiyaning daromadga nisbati BGNE|P/S multiplikatori Checkpoint Therapeutics Inc.|P/S multiplikatori ELEV|Kapitalizatsiyaning daromadga nisbati iCAD ICAD|P/S multiplikatori IKNA (Ikena Oncology, Inc.)|Bozor kapitallashuvining daromadga nisbati NTBL|Viracta Therapeutics, Inc. - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning daromadga nisbati Ascentage Pharma Group Ltd